Complete Guide to Tacrolimus pop Pharmacokinetics
Overview
Tacrolimus pop is a Calcineurin inhibitor (immunosuppressant) used in the Hematology / Transplantation therapeutic area. It is indicated for Pediatric/young adult hematopoietic cell transplantation. Population pharmacokinetic simulator for tacrolimus IV continuous infusion in pediatric and young adult patients undergoing hematopoietic cell transplantation (HCT). Two-compartment model with allometric weight scaling and CYP3A4/5 inhibitor effect. Based on Brooks et al. (2021).
Mechanism of Action
Tacrolimus pop exerts its pharmacological effect by targeting Calcineurin. As a Calcineurin inhibitor (immunosuppressant), it modulates this target to achieve therapeutic efficacy in Pediatric/young adult hematopoietic cell transplantation. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK (2-compartment) models for Tacrolimus pop:
| Parameter | Value |
|---|---|
| Q | intercompartmental clearance (allometric) |
| CL | allometric weight-scaled |
| V1 | central volume (allometric) |
| V2 | peripheral volume (allometric) |
| covariates | Body weight (allometric), CYP3A4/5 inhibitor co-administration |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Tacrolimus pop is administered via the IV continuous infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Hematology / Transplantation therapeutic area, for the treatment of Pediatric/young adult hematopoietic cell transplantation, understanding the pharmacokinetics of Tacrolimus pop is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Tacrolimus pop pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Tacrolimus pop PK Simulator
Explore Tacrolimus pop pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Tacrolimus pop?
The elimination half-life of Tacrolimus pop depends on patient-specific factors. Use our interactive Tacrolimus pop PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Tacrolimus pop administered?
Tacrolimus pop is administered via the IV continuous infusion route. It is indicated for Pediatric/young adult hematopoietic cell transplantation. As a Calcineurin inhibitor (immunosuppressant), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Tacrolimus pop?
Key pharmacokinetic parameters for Tacrolimus pop include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Tacrolimus pop dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Tacrolimus pop PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.